Breast Cancer Outcomes at Aster, 2020-2025: A Transparent Review
Patients deserve honest numbers. Here is how our breast cancer program has performed over the last five years, across every stage at diagnosis, with context on what the numbers mean.
Why we publish our outcomes
Most medical centers do not publish granular outcome data. We think that is a mistake. Patients making cancer treatment decisions deserve to know how a program performs in practice, not just what the marketing copy says. This report covers every breast cancer patient treated at Aster from 2020 through 2025, segmented by stage at diagnosis, age group, and tumor subtype.
Five-year survival by stage
Stage I disease: 97.1% (national benchmark: 99%). Stage II: 91.8% (benchmark: 93%). Stage III: 81.2% (benchmark: 75%). Stage IV: 30.4% (benchmark: 29%). Our results exceed national benchmarks at stages III and IV, driven by multidisciplinary planning and trial enrollment. Our results trail slightly at stages I and II, reflecting a higher proportion of young-onset triple-negative cases referred from outside our system.
Clinical trial participation
We enrolled 320 breast cancer patients in clinical trials from 2020 to 2025. Enrollment rates reached 18.4% of all newly diagnosed patients at our center, substantially above the national average of 5 to 8 percent. Higher trial participation correlates with improved outcomes for stage III and IV disease in our dataset.
What the numbers do not capture
Survival statistics are important but incomplete. This report does not capture patient-reported quality of life, treatment decision satisfaction, or long-term survivorship outcomes. Our 2026 report will add these dimensions using the BREAST-Q and PROMIS instruments we adopted in 2024.
New patients seen within 5 business days.
Our patient navigation team triages every new request, verifies insurance, and matches you to the right specialist.